| Browse All

bioAffinity Technologies, Inc. (BIAFW)

San Antonio, United States | NasdaqCM
0.33 USD -0.03 (-8.333%) ⇩ (April 17, 2026, 3:56 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★☆☆☆☆
Hot Take | April 18, 2026, 11:46 p.m. EDT

BIAFW is a deteriorating fundamental trap with negative growth, massive cash burn, and worthless dividend potential. Despite a recent tick-up to match the fifty-two-week high, the data shows a stagnant trading range, extreme price-to-book undervaluation due to fundamental failure, and no earnings power.

None
Attribute Value
Debt to Equity Ratio 15.95
Revenue per Share 3.58
Beta -0.82
Profit Margins -241.96%
Website https://bioaffinitytech.com

Info Dump

Attribute Value
Address1 3,300 Nacogdoches Road
Address2 Suite 216
Ask 0.0
Ask Size 0
Beta -0.815
Bid 0.0
Bid Size 0
Book Value 1.619
City San Antonio
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.33
Current Ratio 2.603
Custom Price Alert Confidence HIGH
Day High 0.33
Day Low 0.3
Debt To Equity 15.95
Display Name bioAffinity
Ebitda -10,067,672
Ebitda Margins -1.6338401
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.33
Fifty Two Week High Change 0.0
Fifty Two Week High Change Percent 0.0
Fifty Two Week Low 0.3
Fifty Two Week Low Change 0.030000001
Fifty Two Week Low Change Percent 0.1
Fifty Two Week Range 0.3 - 0.33
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 4,266,308
Free Cashflow -4,933,569
Full Exchange Name NasdaqCM
Full Time Employees 57
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.31405002
Gross Profits 1,935,160
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,022-06-28
Language en-US
Long Business Summary bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Long Name bioAffinity Technologies, Inc.
Market us_market
Market State CLOSED
Max Age 86,400
Message Board Id finmb_423045573
Net Income To Common -14,909,754
Open 0.47
Operating Cashflow -9,328,842
Operating Margins -1.9694501
Phone 210 698 5334
Previous Close 0.36
Price Hint 4
Price To Book 0.20382954
Profit Margins -2.41965
Quick Ratio 2.406
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.030000001
Regular Market Change Percent -8.333334
Regular Market Day High 0.33
Regular Market Day Low 0.3
Regular Market Day Range 0.3 - 0.33
Regular Market Open 0.47
Regular Market Previous Close 0.36
Regular Market Price 0.33
Regular Market Time 1,776,455,810
Regular Market Volume 250
Return On Assets -0.75628
Return On Equity -3.01826
Revenue Growth -0.278
Revenue Per Share 3.58
Sand P52 Week Change 0.38150132
Sector
Sector Key
Short Name bioAffinity Technologies, Inc.
Source Interval 15
State TX
Symbol BIAFW
Total Cash 6,449,782
Total Cash Per Share 1.435
Total Debt 1,160,821
Total Revenue 6,161,959
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 250
Website https://bioaffinitytech.com
Zip 78,217